Since 2005, six incretin therapy drugs have been approved by the FDA (United States) and the MHRA (United Kingdom) for T2D treatment: Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide and Tirzepatide, all of which are administered daily or once weekly via subcutaneous injection; although Semaglutide is now also available as an oral medication (Latif et al., 2022). Here, GCG is linked to type 2 diabetes mellitus.